Physician profile
Daniel I Schere
NPI 1639369366
$1,858.53
in general payments reported to CMS, 2019-2025
23 companies · $33.07 in 2025
The $33.07 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2020: $275 · 2021: $532 · 2023: $122 · 2024: $142 · 2025: $33.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $297.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $182.15 | 2019-2025 | Austedo Xr |
| Neurelis, INC. | $168.80 | 2021-2025 | Valtoco |
| Sunovion Pharmaceuticals INC. | $146.80 | 2019-2021 | |
| Abbvie INC. | $138.55 | 2021 | |
| Aquestive Therapeutics, INC. | $137.26 | 2019 | |
| Medtronic USA, INC. | $109.81 | 2019 | |
| Amgen INC. | $100.50 | 2019-2021 | |
| Livanova USA, INC. | $97.03 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $92.07 | 2019-2021 | |
| Sk Life Science, INC. | $82.03 | 2020-2024 | |
| Eisai INC. | $67.59 | 2019-2021 | |
| Allergan, INC. | $64.32 | 2020-2021 | |
| Greenwich Biosciences, INC. | $61.40 | 2019-2021 | |
| Ucb, INC. | $58.27 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $54.47 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuropace, INC. | $49.65 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.31 | 2019-2021 | |
| Ge Healthcare | $44.42 | 2019 | |
| Upsher-Smith Laboratories LLC | $38.31 | 2019-2021 | |
| Lundbeck LLC | $34.71 | 2021 | |
| Avanir Pharmaceuticals, INC. | $33.85 | 2020-2021 | |
| Owp Pharmaceuticals, INC. | $30.31 | 2019 | |
| Zogenix INC. | $18.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Schere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.